Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy-related acute leukemia.

J E Karp1, C B Sarkodee-Adoo

  • 1Department of Medicine, University of Maryland School of Medicine, Baltimore, USA.

Clinics in Laboratory Medicine
|March 7, 2000
PubMed
Summary

Therapy-related acute leukemias develop due to DNA-damaging treatments and have unique features. Understanding their molecular basis can lead to new treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors.

Cell death and differentiation·2015
Same author

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia.

Leukemia·2011
Same author

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.

Leukemia·2010
Same author

Induction of acute lymphocytic leukemia differentiation by maintenance therapy.

Leukemia·2007
Same author

Fluorescent in situ hybridization (FISH) in bone marrow and peripheral blood of leukemia patients: implications for occupational surveillance.

Mutation research·2007
Same author

JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.

Leukemia·2006

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Therapy-related acute leukemias (t-AL) are a distinct subtype of leukemia.
  • These leukemias arise following treatment with DNA-damaging agents, such as chemotherapy or radiation therapy.
  • t-AL exhibit unique molecular, genetic, and clinico-pathologic characteristics compared to de novo leukemias.

Purpose of the Study:

  • To dissect the pathogenetic basis of therapy-related leukemias.
  • To elucidate the molecular mechanisms underlying DNA damage-induced leukemogenesis.
  • To explore potential molecular targets for innovative treatment approaches for t-AL.

Main Methods:

  • Review and analysis of existing literature on therapy-related leukemias.
  • Elucidation of molecular mechanisms involving DNA damage and subsequent genetic aberrations.
  • Correlation of molecular findings with clinical syndromes and outcomes.

Main Results:

  • DNA-damaging agents induce specific molecular and genetic alterations that drive leukemogenesis.
  • These aberrations manifest as distinct clinico-pathologic features in therapy-related acute leukemias.
  • Identification of key molecular pathways and targets implicated in the development of t-AL.

Conclusions:

  • Therapy-related acute leukemias are mechanistically linked to DNA damage.
  • Understanding these molecular pathways is crucial for developing targeted therapies.
  • Further research into molecular targets may improve treatment strategies and patient outcomes for t-AL.

Related Experiment Videos